This is a working overview of immunomodulatory peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-01-24 and is reviewed periodically as new material appears.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
| Property | Value | Notes |
|---|---|---|
| Detection wavelength | 214 nm | Peptide bond absorption; 280 nm is not useful. |
| Confirmatory method | Electrospray mass spectrometry | Verifies mass near 3108 Da. |
| Solution stability | Limited at room temperature | Aqueous solutions degrade faster than powder. |
| Recommended storage | -20 °C | For lyophilized powder; protect from moisture. |
| Purity criterion | ≥95% by RP-HPLC | Typical research-grade specification. |
The activity of this peptide is generally described as immunomodulatory rather than directly antimicrobial. Experimental work links it to signaling through certain Toll-like receptors on dendritic cells and to downstream maturation of antigen-presenting cells. Reported effects include expansion of T cell subsets, shifts in cytokine profiles, and increased natural killer cell activity. These observations come largely from cell culture and animal models, and the precise receptor-level events in humans remain incompletely characterized.
The compound has been investigated as an adjunct in chronic viral hepatitis and as a vaccine adjuvant, with results that vary by study design and population. Regulators in some countries have approved a synthetic form for specific indications, while other agencies have not. Whether the peptide produces consistent clinical benefit across diverse patient groups is still an open question, and many trials have been small. Its status is therefore best described as investigational in many contexts and established only narrowly.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
A number of these women would go on to join a class action lawsuit, Madrigal v. Quilligan, discussed below. These Mexican and Mexican-American women were given the stereotype as "hyper-fertile" and were believed to lack the knowledge of birth control methods due to the high numbers of teen pregnancies occurring within their community. At the Hospital of LA County+USC, coercive sterilization was justified as it was an attempt to control the birthrate of these women. In 1998 the US government performed a census and multiyear analysis of Latino births and found the women of Mexican origin displayed the highest rate of childbirth compared to other Latina women. From these statistics, the "Save our State" campaign arose and worked to enforce more eugenic sterilization of these women. In 1973 an investigation by progressive anti-sterilization advocacy groups discovered the stories of Mary Alice's and Minnie Lee Relf's sterilization. This story was released by the Southern Poverty Law Center and led to the discovery of 16 thousand women and 8,000 men being sterilized using federal funds in 1972. In addition to this finding, they found more than three hundred of these patients were under the legal age of 21. Following this discovery and exposure, in 1977 Mexican-American began coming forth to file lawsuits in relation to coercive sterilization they faced while in labor. In 1979 a bill to repeal the eugenics laws passed that legalized sterilization was proposed to the legislature in California.
It is an optical analytical technique that analyzes the interference pattern of white light reflected from two surfaces: a layer of immobilized protein on the biosensor tip, and an internal reference layer. Any change in the number of molecules bound to the biosensor tip causes a shift in the interference pattern that can be measured in real-time, providing detailed information regarding the kinetics of association and dissociation of the two molecules as well as the affinity constant for the protein interaction (ka, kd and Kd). Due to sensor configuration, the technique is highly amenable to both purified and crude samples as well as high throughput screening experiments. The detection method can also be used to determine the molar concentration of analytes. Protein activity determination by NMR multi-nuclear relaxation measurements, or 2D-FT NMR spectroscopy in solutions, combined with nonlinear regression analysis of NMR relaxation or 2D-FT spectroscopy data sets. Whereas the concept of water activity is widely known and utilized in the applied biosciences, its complement—the protein activity which quantitates protein–protein interactions—is much less familiar to bioscientists as it is more difficult to determine in dilute solutions of proteins; protein activity is also much harder to determine for concentrated protein solutions when protein aggregation, not merely transient protein association, is often the dominant process.
=== Metabolic syndrome === Multiple cross-sectional studies have found associations between early androgenic alopecia, insulin resistance, and metabolic syndrome, with low HDL being the component of metabolic syndrome with highest association. Linolenic and linoleic acids are 5 alpha reductase inhibitors. Premature androgenic alopecia and insulin resistance may be a clinical constellation that represents the male homologue, or phenotype, of polyendocrine metabolic ovarian. Others have found a higher rate of hyperinsulinemia in family members of women with polyendocrine metabolic ovarian. With early-onset androgenetic alopecia having an increased risk of metabolic syndrome, poorer metabolic profiles are noticed, including metrics for body mass index, waist circumference, fasting glucose, blood lipids, and blood pressure. In support of the association, finasteride improves glucose metabolism and decreases glycated hemoglobin HbA1c, a surrogate marker for diabetes mellitus. The low SHBG seen with premature androgenic alopecia is also associated with, and likely contributory to, insulin resistance, and for which it still is used as an assay for pediatric diabetes mellitus. Obesity leads to upregulation of insulin production and a decrease in SHBG. Further reinforcing the relationship, SHBG is downregulated by insulin in vitro, although SHBG levels do not appear to affect insulin production. In vivo, insulin stimulates both testosterone production and SHBG inhibition in normal and obese men.
=== EC 1.18.1 With NAD+ or NADP+ as acceptor === EC 1.18.1.1: rubredoxin—NAD+ reductase EC 1.18.1.2: ferredoxin—NADP+ reductase EC 1.18.1.3: ferredoxin—NAD+ reductase EC 1.18.1.4: rubredoxin—NAD(P)+ reductase EC 1.18.1.5: Putidaredoxin—NAD+ reductase EC 1.18.1.6: adrenodoxin-NADP+ reductase EC 1.18.1.7: ferredoxin—NAD(P)+ reductase (naphthalene dioxygenase ferredoxin-specific) EC 1.18.1.8: Now EC 7.2.1.2, ferredoxin—NAD+ oxidoreductase (Na+-transporting)
Sources: en.wikipedia.org
A small N-terminal domain (160 amino-acid residues) A large C-terminal domain (240 amino-acid residues) Each noncovalently-associated monomer subunit consists of both domains. The subunits interact with each other through about 20 hydrogen bonds and four ion pairs, providing stability to the dimer. The two domains in each monomer subunit are more loosely connected, with only six hydrogen bonds and one ion pair between them, and no intra- or intermolecular disulfide bonds. Looking more closely at the two domains, the following structures were described in 1988:
The president of Serbia and Montenegro (Serbian: Предс(ј)едник Србије и Црне Горе, romanized: Preds(j)ednik Srbije i Crne Gore) was the head of state of Serbia and Montenegro. From its establishment in 1992 until 2003, when the country was reconstituted as a confederacy (state union) via constitutional reform, the head of state was known as the president of the Federal Republic of Yugoslavia (Serbian: Предс(ј)едник Савезне Републике Југославије, romanized: Preds(j)ednik Savezne Republike Jugoslavije). With the constitutional reforms of 2003 and the merging of the offices of head of government and head of state, the full title of the president was President of Serbia and Montenegro and Chairman of the Council of Ministers of Serbia and Montenegro (Serbian: Предс(ј)едник Србије и Црне Горе / Предс(ј)едник Сав(ј)ета министара Србије и Црне Горе). In 2006 the office was abolished as the state union was dissolved, with Serbia and Montenegro becoming independent countries.
Due to the high sulfur content of the Athabasca Oil Sands, stockpiles of elemental sulfur from this process exist throughout Alberta, Canada. Another way of storing sulfur is as a binder for concrete, the resulting product having some desirable properties (see sulfur concrete). The world production of sulfur in 2011 amounted to 69 million tonnes (Mt), with more than 15 countries contributing more than 1 Mt each. Countries producing more than 5 Mt are China (9.6), the United States (8.8), Canada (7.1) and Russia (7.1). Production has been slowly increasing from 1900 to 2010; the price was unstable in the 1980s and around 2010.
Sources: en.wikipedia.org
Sedating antihistamines like cyproheptadine may have additive effects with other CNS depressants like such as alcohol, hypnotics, sedatives, tranquilizers, and anxiolytics. Monoamine oxidase inhibitors (MAOIs) may prolong and intensify the anticholinergic effects of antihistamines like cyproheptadine. However, cyproheptadine is safe to use in the treatment of serotonin syndrome occurring with MAOIs. Cyproheptadine, due to its serotonin 5-HT2A receptor antagonism, may be useful as a hallucinogen antidote against serotonergic psychedelics or as a so-called "trip killer". The drug has been clinically studied in combination with the serotonergic psychedelic dimethyltryptamine (DMT). In an early study, cyproheptadine partially blocked the hallucinogenic effects of DMT in 2 of 3 subjects. In a follow-up study, pretreatment with cyproheptadine in 5 subjects failed to reduce the psychoactive effects of DMT and instead was found to actually intensify its effects in some cases, although the duration of DMT seemed to be shortened. Subsequently, Rick Strassman and colleagues studied cyproheptadine in combination with DMT in 8 subjects and found that the hallucinogenic effects of DMT were not magnified but were reduced. However, owing to the pronounced sedative effects of cyproheptadine, it was difficult to tell how much of cyproheptadine's effect was due to antagonism of DMT versus simple general tranquilization. Overall, the findings have been described as inconclusive and higher doses of cyproheptadine being precluded by the drug's sedative effects.
Brine pockets which are accessed by smaller pores can experience a higher abundance of photoautotrophic protists as well as smaller heterotrophic protists due to limited grazing pressure by the reduced abundance of large predators, such as large ciliates and metazoan predators.
=== Temperature Tuesday === In 2010, Runza introduced their Temperature Tuesdays promotion. In January and February, the coldest temperature at a Runza at 6AM would be the price of an original Runza sandwich with the purchase of medium french fries and a drink (ex. if the coldest temperature at a Runza was 11° at Ogallala, an original Runza would be 11¢ with purchase of a medium fry and drink). If the temperature was below zero, a Runza would be free with the purchase of a medium fry and drink. The promotion has since been shortened to only take place in January.
The radical shift in the connotation of "genetic engineering" from an emphasis on the inherited characteristics of people to the commercial production of proteins and therapeutic drugs was nurtured by Joshua Lederberg. His broad concerns since the 1960s had been stimulated by enthusiasm for science and its potential medical benefits. Countering calls for strict regulation, he expressed a vision of potential utility. Against a belief that new techniques would entail unmentionable and uncontrollable consequences for humanity and the environment, a growing consensus on the economic value of recombinant DNA emerged.
Sources: en.wikipedia.org
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.
The lyophilized powder is usually stored at -20 °C or below. Dissolved solutions are less stable and should be prepared fresh when possible. Freeze-thaw cycling can reduce integrity.
It lacks aromatic residues, so it does not absorb strongly at 280 nm. Its negative charge and hydrophilic nature can affect chromatographic retention. These properties require method development for reliable separation.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.